Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Sanofi Expected to Overtake Pfizer as World’s Top Drug Maker in 2012: Evaluate Pharma
November 10, 2011
- Seikagaku to Conduct Add’l PIII Trial for Lumbar Disc Herniation Treatment SI-6603
November 10, 2011
- Toho HD’s Sales Increased to ¥2 Bil. in 1st-Half Driven by Dispensing Pharmacy Business
November 9, 2011
- Toho Holdings' Matsutani Says His Company Will Protect Its Own Prices
November 9, 2011
- Operating Profit Rate for Top-4 Wholesalers Slips to 0.39% in April-September
November 9, 2011
- Astellas, RIKEN to Explore, Jointly Develop Novel Drug Targets for AD
November 9, 2011
- Yakult, LivTech Enter into Option Agreement for Anti-Cancer Monoclonal Antibody Development Program
November 9, 2011
- Towa Pharmaceutical Developing Lipitor Generic Version OD Tablets
November 9, 2011
- Nihon Chouzai Planning to Open 150-200 Stores a Year: President Mitsuhara
November 9, 2011
- CMIC Reports Increases in Sales and Profits Driven by CRO Business
November 8, 2011
- Nichi-Iko to Change Company Structure to Strengthen Sales of Generic Drugs
November 8, 2011
- Kaken to Enhance Detailing Activities for GPs Aiming at Sales Expansion for Lipidil, Generics
November 8, 2011
- Towa Pharmaceutical’s New Business Plan is “Groundwork for Future Progress”
November 8, 2011
- Suzuken President Ota Says Wholesale Business Recovery Crucial
November 8, 2011
- Towa Apr-Sep Earnings Limited on Break in Impact of Premium Revision
November 8, 2011
- Intellim Ties Up with SMO Iberica, Aiming to Enter US Market in 2012
November 8, 2011
- Pfizer Japan Applies for Additional Indication for Sutent for pNET Designated as Orphan Disease
November 8, 2011
- Prices Should Remain Stable in 2nd-Half: Pres. Ishiguro of Alfresa HD
November 8, 2011
- Kyorin HD: Both Sales, Profits Remain Virtually Unchanged
November 8, 2011
- Eli Lilly, Amylin to Terminate Collaboration in Field of Diabetes
November 8, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…